vimarsana.com

Latest Breaking News On - Cosmo pharmaceuticalsnv key - Page 1 : vimarsana.com

Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)

Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory Admission Cosmo announces submission of Winlevi® to .

France generalUnited statesHazel winchesterDiana harbortSun pharmaEuropean medicines agencyEuropean unionCosmos dermatology divisionCosmo pharmaceuticalsnv keyEuropean medicine agencyCosmo pharmaceuticalsUnited states food drug administrationRegulatory admissionInvestigators global assessmentMarketing authorisation applicationMarketing authorization

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europ

Cosmo Pharmaceuticals N.V. / Key word(s): Contract27-Sep-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement. Cassiopea, the subsidiary of Cosmo, will be responsible for Centralized Marketing Authorization at European Medic.

United statesCzech republicSouth africaFrance generalNorth yorkshireUnited kingdomHazel winchesterGlenn saldanhaUdaykumar murthyUnited states food drug administrationCorporate communicationsCosmo pharmaceuticalsnv keyEuropean medicines agencyCosmo pharmaceuticalsLinkedin glenmark pharmaceuticalsIndian pharmaceuticals

Termination of Agreement for Rifamycin SV MMX® with Dr Falk Pharma

Cosmo Pharmaceuticals N.V. / Key word(s): AgreementTermination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma 04.09.2023 / 05:45 GMT/BSTDublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr..

France generalHazel winchesterFalk pharmaMulti matrix technologyCosmo pharmaceuticalsnv keyCosmo pharmaceuticalsTraveler diarrheaLondon healthcare conferenceCommunication european midcap event

Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA

Cosmo Pharmaceuticals N.V. / Key word(s): AgreementCosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions 04.09.2023 / 06:00 GMT/BSTDublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Adalvo Ltd. (“Adalvo.

France generalHazel winchesterRedhill biopharmaAdalvo ltdMulti matrix technologyCosmo pharmaceuticalsHuman resources corporate communicationsCosmo pharmaceuticalsnv keySupply agreementNorth africaLatin americaTraveler diarrheaLondon healthcare conferenceCommunication european midcap eventHuman resources

Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alo

Cosmo Pharmaceuticals N.V. / Key word(s): StudyCosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia 29.06.2023 / 06:15 GMT/BSTDublin, Ireland – June 29, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the beginning of the phase I.

France generalUnited statesUnited kingdomDiana harbortHazel winchesterClascoterone cortexoloneCosmo pharmaceuticalsnv keyCosmo pharmaceuticalsCosmo dermatology divisionTarget area hair countPatient reported outcomeDermatology divisionEpidemiology forecastYear resultsLondon healthcare conferenceCommunication european midcap event

vimarsana © 2020. All Rights Reserved.